 Home > Encyclopedia > Iopromide

Iopromide

Iopromide structure

CAS No:
73334-07-3
Formula:
C18H24I3N3O8
Chemical Name:
Iopromide
Synonyms:
1,3-Benzenedicarboxamide,N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(2-methoxyacetyl)amino]-N1-methyl-;1,3-Benzenedicarboxamide,N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(methoxyacetyl)amino]-N-methyl-;N1,N3-Bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(2-methoxyacetyl)amino]-N1-methyl-1,3-benzenedicarboxamide;Iopromide;SHL 414C;Ultravist;Ultravist 370;Ultravist 300;ZK 35760;Iopromidum;1-N,3-N-Bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(2-methoxyacetyl)amino]-3-N-methylbenzene-1,3-dicarboxamide
Categories:
Active Pharmaceutical Ingredients > Diagnostic Agents

Description

Iopromide is a water-soluble, non-ionic, monomeric, low-osmolar, iodine-based contrast medium for intravascular administration.

Iopromide is a dicarboxylic acid diamide that consists of N-methylisophthalamide bearing three iodo substituents at positions 2, 4 and 6, a methoxyacetyl substituent at position 5 and two 2,3-dihydroxypropyl groups attached to the amide nitrogens. A water soluble x-ray contrast agent for intravascular administration. It has a role as a radioopaque medium, a nephrotoxic agent, a xenobiotic and an environmental contaminant. It is an organoiodine compound and a dicarboxylic acid diamide. It derives from an isophthalamide and a glycerol.|Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the path of flow of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Available as the FDA-approved product Ultravist, iopromide is used in radiographic studies such as intra-arterial digital subtraction angiography (IA-DSA), cerebral and peripheral arteriography, peripheral venography, excretory urography, brain computer tomography (CT), coronary arteriography, left ventriculography, visceral angiography, and aortography.|Iopromide is a Radiographic Contrast Agent. The mechanism of action of iopromide is as a X-Ray Contrast Activity.|Iopromide is a contrast medium.

Iopromide Basic Attributes

Molecular Weight：

791.11

Exact Mass：

791.11

EC Number：

277-385-9

UNII：

712BAC33MZ

DSSTox ID：

DTXSID0023163

NCI Thesaurus Code：

C1137

ATC Code：

V08AB05|V - Various

HScode：

2924299090

Characteristics

PSA：

169

XLogP3：

-2.1

Appearance：

Density：

2.2±0.1 g/cm3

Melting Point：

broad (160°C transition)

Boiling Point：

840.9ºC at 760 mmHg

Flash Point：

462.4±34.3 °C

Refractive Index：

1.710

Storage Conditions：

Hygroscopic, -20°C Freezer, Under Inert Atmosphere

Toxicity：

LD50 in mice, rats (g iodine/kg body weight): 16.5, 11.4 i.v. (Muetzel)

Collision Cross Section：

212.3 Å² [M-H]-

Safety Information

Packing level：

Ⅲ

Transport codes：

UN 3077 9 / PGIII

wgk germany：

hazard class code：

50/53

safety instructions：

60-61

RTECS Number：

CZ2230000

Marks：

Stability/Shelf Life：

Hygroscopic

Precautionary statement(s)：

P273-P501

Hazard Statements：

H410

GHS Classification：

|Warning|H400 (100%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]|P273, P391, and P501|Aggregated GHS information provided by 39 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Toxicity

Toxicity Summary：

Most common adverse reactions (>1%) are headache, nausea, injection site and infusion site reactions, vasodilatation, vomiting, back pain, urinary urgency, chest pain, pain, dysgeusia, and abnormal vision. Inadvertent intrathecal administration may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema.

Protein Binding：

Plasma protein binding of iopromide is 1%.

Drug Information

Drug Indication：

Iopromide, as the product Iovist, is indicated for use as an X-ray contrast agent in the following procedures: Intra-arterial digital subtraction angiography (IA-DSA) (150 mg I/mL) Cerebral arteriography and peripheral arteriography (300 mg I/mL) Coronary arteriography and left ventriculography, visceral angiography and aortography (370 mg I/mL) Peripheral venography (240 mg I/mL) Excretory urography (300 mg I/mL) Contrast computed tomography (CT) imaging of head and body (300 mg I/mL and 370 mg I/mL)|FDA Label

MeSH：

Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)

Absorption：

Following administration, the degree of contrast enhancement is directly related to the iodine content in the administered dose; peak iodine plasma levels occur immediately following rapid intravenous injection. Iodine plasma levels fall rapidly within 5 to 10 minutes, which can be accounted for by the dilution in the vascular and extravascular fluid compartments. Contrast enhancement appears to be greatest immediately after bolus injections (15 seconds to 120 seconds). Thus, greatest enhancement may be detected by a series of consecutive two-to-three second scans performed within 30 to 90 seconds after injection (that is, dynamic computed tomographic imaging). Injection may be visualized in the renal parenchyma within 30–60 seconds following rapid intravenous injection. Opacification of the calyces and pelves in patients with normal renal function becomes apparent within 1–3 minutes, with optimum contrast occurring within 5–15 minutes.|The amounts excreted unchanged in urine represent 97% of the dose in young healthy subjects. Only 2% of the dose is recovered in the feces. Similar recoveries in urine and feces are observed in middle-aged and elderly patients. This finding suggests that, compared to the renal route, biliary and/or gastrointestinal excretion is not important for iopromide. During the slower terminal phase only 3% of the dose is eliminated; 97% of the dose is disposed of during the earlier phases, the largest part of which occurs during the main elimination phase.|16 L|The mean total and renal clearances are 107 mL/min and 104 mL/min, respectively.

Metabolism/Metabolites：

Iopromide is not metabolized.

Biological Half-Life：

After intravenous administration to healthy young volunteers, plasma iopromide concentration time profile shows an initial distribution phase with a half-life of 0.24 hour; a main elimination phase with a half-life of 2 hours; and a terminal elimination phase with a half-life of 6.2 hours.

Mechanism of Action：

Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the path of flow of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs.

MeSH Entry Terms：

Clarograf

Iopromide Use and Manufacturing

Uses

Iopromide, also known as Uvixine and Iopramide, is a non-ionic hypotonic contrast agent that was launched in Switzerland in 1986. This product can reduce the adverse reactions caused by high osmotic pressure. The solution is neutral, so it will not affect the charged protein and cell membrane structure, nor will it interfere with the electrolyte balance in the body, so it has little effect on red blood cells, endothelial cells and body fluids. Its advantages are: directly used for angiography, basically no pain; good tolerance of endothelial cells; slight adverse reactions; almost no effect on heart rhythm; and no reduction of myocardial contractility; good tolerance of the nervous system; oral administration of the drug The fluid is not absorbed by the gastrointestinal tract. It is injected into the blood vessel and quickly distributed in the extracellular fluid. A few minutes after intravenous injection, the drug concentration in the kidney reaches its peak, followed by the blood and liver, and the least in the muscle.

Use Classification：

Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients

Computed Properties

Molecular Weight:791.1
XLogP3:-2.1
Hydrogen Bond Donor Count:6
Hydrogen Bond Acceptor Count:8
Rotatable Bond Count:11
Exact Mass:790.8698
Monoisotopic Mass:790.8698
Topological Polar Surface Area:169
Heavy Atom Count:32
Complexity:647
Undefined Atom Stereocenter Count:2
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Drug Function and Efficacy

Iopromide is a new type of non-ionic low-osmotic contrast agent suitable for angiography, brain and abdominal CT scans, and urethrography. Animal experiments have shown that it has good tolerance. Due to its low permeability, it causes less pain and improves clinical tolerance in the application of selective peripheral artery and cerebral artery angiography.

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Iopromide Injection
Ingredients	Main ingredient: Iopromide. Molecular formula: C18H24I3N3O8 Molecular weight: 791.12
Indication	The use of contrast media may cause transient renal insufficiency, which can cause lactic acidosis in diabetic patients taking glucose-lowering drugs (metformin). As a precaution, biguanide glucose-lowering drugs should be discontinued 48 hours before the use of contrast media, and only resumed after renal function stabilizes.
Specifications	75 ml: 46.76 g

Iopromide Injection
Specifications	100ml:76.89g

Iopromide Injection
Ingredients	Main ingredient: Iopromide. Molecular formula: C18H24I3N3O8 Molecular weight: 791.12
Indication	The use of contrast media may cause transient renal insufficiency, which can cause lactic acidosis in diabetic patients taking glucose-lowering drugs (metformin). As a precaution, biguanide glucose-lowering drugs should be discontinued 48 hours before the use of contrast media, and only resumed after renal function stabilizes.
Specifications	75 ml: 46.76 g

See More Related Drugs

Registered Holders

Bayer Ag

Finland
Active
BrightGene Pharmaceutical Co., Ltd.

China
Active
Zhejiang Hichi Pharmaceutical Corporation Limited

China
Active

See More Registered Holders

Recommended Suppliers of Iopromide

Shandong Airuike Chemical Co., Ltd. Contact Supplier

CN
2 YRS

Business licensed

Trader Supplier of api,Intermediates,Organic Chemistry,Inorganic Chemistry,Daily Chemicals,Cosmetic Raw Materals,CATALYST AND AUXILIARY,FLAVORS AND FRAGRANCES,Chemical Pesticides,ADDITIVE

Iopromide CAS 73334-07-3

CAS No.: 73334-07-3

Grade: Pharmaceutical Grade

Content: 99%

Inquiry
BrightGene Health Technology Co., Ltd Contact Supplier

CN
4 YRS

Business licensed Certified factory

Manufactory Supplier of APIs,Veterinary,Cosmetic Ingredients,Peptides,intermediates,food ingredients

Lopromide GMP DMF Ready 99%

CAS No.: 73334-07-3

Grade: Pharmaceutical Grade

Content: 99%

Inquiry
Changzhou Xuanming Pharmaceutical Techno Contact Supplier

CN
5 YRS

Business licensed

Trader Supplier of Peptides,Chemicals,API,Additives

Pharmaceutical intermediate Iopromide 73334-07-3

CAS No.: 73334-07-3

Grade: Pharmaceutical Grade

Content: 99%

Inquiry
Sinoway Industrial Co., Ltd. Contact Supplier

CN
4 YRS

Business licensed

Trader Supplier of Semaglutide,APIs,Alpha GPC,Liraglutide,Herbal Extract,Nervonic Acid,Coenzyme Q10,Herbal extracts,Guaiazulene,CDMO services,Pharmaceutical intermediates,Healthcare & Food Supplements,NAD,L-theanine,Glyoxylic acid,L-Glutathione reduced,Spermidine,Diosmin,Gliclazide,Cosmetic Raw Materials,Citicoline Sodium,Nervonic Acid

Iopromide

CAS No.: 73334-07-3

Grade: Pharmaceutical Grade

Content: 98%

Inquiry
ROYAL PHARM Contact Supplier

CN
4 YRS

Business licensed

Trader Supplier of additives,pharmaceutical chemicals,organic intermediate,chemical intermediates,Pharmaceutical Intermediates,catalyst,API

Iopromide CAS No.73334-07-3

CAS No.: 73334-07-3

Grade: Pharmaceutical grade

Content: 99%

Inquiry